152 related articles for article (PubMed ID: 33797309)
1. Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report.
Suwa S; Tomita R; Kataoka K; Ueno S
Ocul Immunol Inflamm; 2022 Aug; 30(6):1522-1526. PubMed ID: 33797309
[TBL] [Abstract][Full Text] [Related]
2. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
Wang JN; Zhang Y; Huang CY; Li K; Yu XB
BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
Ushio R; Yamamoto M; Miyasaka A; Muraoka T; Kanaoka H; Tamura H; Kaneko A; Izawa A; Hirama N; Teranishi S; Manabe S; Inoue T; Shibata K; Sugiura Y; Kudo M; Kaneko T
Intern Med; 2021 Nov; 60(22):3593-3598. PubMed ID: 34092725
[TBL] [Abstract][Full Text] [Related]
4. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
[TBL] [Abstract][Full Text] [Related]
5. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
[TBL] [Abstract][Full Text] [Related]
6. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
Kikuchi R; Kawagoe T; Hotta K
BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
[TBL] [Abstract][Full Text] [Related]
8. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
9. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
10. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
11. Vogt-Koyanagi-Harada disease during chemoimmunotherapy for non-small cell lung cancer.
Kurono Y; Takeda T; Kunimatsu Y; Tani N; Hashimoto I; Hirose K
Respirol Case Rep; 2020 Apr; 8(3):e00545. PubMed ID: 32128216
[TBL] [Abstract][Full Text] [Related]
12. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.
Caso F; Rigante D; Vitale A; Costa L; Bascherini V; Latronico E; Franceschini R; Cantarini L
Clin Rheumatol; 2015 Oct; 34(10):1817-20. PubMed ID: 25224382
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin therapy in Vogt Koyanagi Harada disease.
Wakefield D; McCluskey P; Reece G
Aust N Z J Ophthalmol; 1990 May; 18(2):137-42. PubMed ID: 2390240
[TBL] [Abstract][Full Text] [Related]
14. Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab.
Huang Y; Khan F; Saraiya NV; Punjabi OS; Gulati V; Erickson AR; Yeh S
J Immunother; 2023 Oct; 46(8):295-298. PubMed ID: 37315200
[TBL] [Abstract][Full Text] [Related]
15. Vogt-Koyanagi-Harada disease during prolonged intermittent steroid therapy for chronic obstructive pulmonary disease: a case report.
Akulwar S; Gupta H; Pustake M; Vidhale T; Lahane S; Rohan PJ
Pan Afr Med J; 2021; 39():101. PubMed ID: 34512837
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune uveitis in Behçet's disease and Vogt-Koyanagi-Harada disease differ in tissue immune infiltration and T cell clonality.
Kang H; Sun H; Yang Y; Tuong ZK; Shu M; Wei Y; Zhang Y; Yu D; Tao Y
Clin Transl Immunology; 2023; 12(9):e1461. PubMed ID: 37720629
[TBL] [Abstract][Full Text] [Related]
17. HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors.
Takeuchi M; Meguro A; Nakamura J; Chikagawa R; Osada R; Shibuya E; Hasumi Y; Yamada N; Ishihara M; Mizuki N
Sci Rep; 2023 Aug; 13(1):13580. PubMed ID: 37604934
[TBL] [Abstract][Full Text] [Related]
18. Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
Rujkorakarn P; Patamatamkul S
J Fr Ophtalmol; 2023 Mar; 46(3):207-210. PubMed ID: 36775731
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
Tieger MG; Eliott D; Cakir B; Dahrouj M
Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
[TBL] [Abstract][Full Text] [Related]
20. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Accorinti M; Saturno MC; Manni P
Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
